The Rising Price of Eating Well: Why a Healthy Diet Costs More—Yet Remains Out of Reach for Billions
By Business Access TV News DeskJanuary 13, 2026 A healthy diet is widely promoted as one…


In a significant victory for the Biden administration, the United States has secured substantial price reductions for 10 top-selling prescription drugs covered by Medicare, achieving discounts as high as 79%. This initiative is expected to save $6 billion in the first year alone, marking a critical step in President Joe Biden’s broader strategy to tackle the escalating cost of medications. This move is particularly timely as it comes in the lead-up to the November elections.
President Biden, speaking at an event in Largo, Maryland, celebrated this achievement, highlighting it as a major success of the Inflation Reduction Act, a landmark piece of legislation passed in 2022. This law, for the first time, allowed Medicare to negotiate prices for some of the most expensive drugs in its coverage, benefiting the 66 million people enrolled in the program. The newly negotiated drug prices are set to take effect in 2026.
During the event, Biden was joined by Vice President Kamala Harris, who played a crucial role in the passage of the law, casting the tie-breaking vote in the Senate. Biden praised the administration’s efforts, stating, “We finally beat Big Pharma.” He emphasized that these savings would directly address public concerns over high drug prices—a key issue in the upcoming presidential race, where Harris is expected to be a prominent figure.
Vice President Harris underscored her long-standing commitment to reducing prescription drug costs, drawing on her experience as California’s Attorney General, where she held pharmaceutical companies accountable for unfair practices. “Medicare can now use its collective bargaining power to negotiate lower drug prices, leveling the playing field with Big Pharma,” Harris remarked.
The discounts negotiated under this plan reflect reductions from the individual list prices of the drugs. Although existing rebates or discounts the government may already receive were not included in these reductions, the overall savings do consider these factors. Harris highlighted her previous efforts against pharmaceutical giants, noting that this recent achievement builds on her career-long dedication to fighting for lower drug costs.
The event also served as a platform for Biden to rally political support, where he praised Harris and criticized Republican opposition to the Medicare negotiation provisions. Republican leaders, including House Speaker Mike Johnson, have criticized the initiative, labeling it as “price fixing” and arguing that it could potentially increase healthcare costs and hinder innovation within the American pharmaceutical industry.
The pharmaceutical industry has responded with strong opposition, with several companies filing lawsuits against the administration, warning that some of their drug development programs may be adversely affected. Despite these challenges, the administration is pushing forward, with the next round of Medicare drug price negotiations slated to begin in February, targeting an additional 15 drugs.

This Post Has 0 Comments